

Author: Klotz Daniel
Publisher: Informa Healthcare
ISSN: 1473-7140
Source: Expert Review of Anticancer Therapy, Vol.13, Iss.4, 2013-04, pp. : 461-468
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Anticancer therapy relies on targeting highly proliferative cells. Commonly used chemotherapy does not selectively target individual cancer cells. The identification of distinct cancer stem cells that have the unique ability to engraft tumors and maintain cancer self-renewal may prove vital in the development of novel and selective anticancer therapy. Therefore, the discovery of colorectal cancer stem cell markers has attracted much attention. However, it is still controversial whether current markers for cancer cell subpopulations are selectively labeling cancer stem cells, whether these markers contribute to cancer stem cell function and how many cells within tumors maintain this stemness. For this reason, novel anticancer drug approaches need to be considered, that target selective cell death pathways, the tissue microenvironment and, additionally, multiple specific cancer (stem) cell markers. This triple approach of anticancer therapy may contribute to novel chemotherapeutic strategies and improve the understanding of human intestinal tumorigenesis; in particular, the distinct contribution of human cancer stem cells.
Related content




Cancer stem cells and cancer therapy
Tumor Biology, Vol. 32, Iss. 3, 2011-06 ,pp. :


Mesenchymal Stem Cells for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Iss. 3, 2013-01 ,pp. :


Implications of cancer stem cells in the treatment of cancer
By Pan Chong-xian Zhu Wei Cheng Liang
Future Oncology, Vol. 2, Iss. 6, 2006-12 ,pp. :


Targeted therapy against cancer stem cells (Review)
Oncology Letters, Vol. 10, Iss. 1, 2015-07 ,pp. :